Peter T. Nower

Innovative Research Scientist with a strong background in cellular and biochemical assay development and optimization, data analysis, drug discovery, and high-thoughput screening. Experience with molecular biology and protein purification. Knowledged in all stages of the drug discovery process.

Strengths include analytical problem-solving and communication skills.

Past work has led to significant advancements in scientific understanding and practical applications.

Patent recipient for Hepatitis C Virus Assays: Min Gao, Julie A. Lemm, Donald R. O’Boyle II, Peter Nower, Karen Rigat, Jin-Hua Sun, Hepatitis C Virus Assays, United States Patent # 7,195,885, March 27, 2007.

Instrumental scientist on the drug discovery team involved in the discovery, optimization, characterization and development of Bristol-Myers Squibb’s first-in-class Hepatitis C virus (HCV) NS5a inhibitor, Daklinza (Daclatasvir, BMS-790052).

Pivotal research scientist and team member who contributed to the discovery of ARV-806, a PROTAC degrader, that selectively targets G12D mutant form of KRAS found in cancer and was approved by the FDA to enter clinical trials.

Essential scientist and team member in the development of a PAN KRAS PROTAC degrader targeting pancreatic, colon and lung cancers.

Excited about new challenges combining my scientist expertise and leadership skills to help grow an organization while developing and mentoring new scientists.

Hepatitis C Virus Assays, Min Gao, Julie A. Lemm, Donald R. O’Boyle II, Peter Nower, Karen Rigat, Jin-Hua Sun, 7,195,885, 03/27/07

BMS Triumph LDOC Award, Development of a cell-based, proprietary replicon system for measuring the activity of inhibitors against Hepatitis C virus and for identifying two novel classes

• KRAS-targeted PROTAC degraders are broadly efficacious against KRAS-dependent tumor models, Kathryn Smith, Andrea Lopez-Arroyo, Jason Berk, Peter Hegan, Peter Nower, Samantha Tice, Aurelie Moutran, Jennifer Pizzano, Amanda Dowtin, Mark Bookbinder, Elizabeth Bortolon, Greg Cadelina, Fazlul Karim, Katie Digianantonio, Miklos Bekes, Jesus Medina, Mol Cancer Res, 2023, 21, 5_Supplement, PR09, https://doi.org/10.1158/1557-3125.RAS23-PR09
• Synergistic activity of combined NS5A inhibitors, Donald O'Boyle, Peter Nower, Min Gao, Robert Fridell, Chunfu Wang, Piyasena Hewawasam, Omar Lopez, Yong Tu, Nicholas Meanwell, Makonen Belema, Susan Roberts, Mark Cockett, Jin-Hua Sun, Antimicrobial Agents and Chemotherapy, 10.1128/AAC.02639-15
• Resensitizing Daclatasvir-Resistant Hepatitis C Variants by Allosteric Modulation of NS5A, Jin-Hua Sun, Donald R. O’Boyle II, Robert Fridell, David R. Langley, Chunfu Wang, Susan Roberts, Peter Nower, Benjamin M. Johnson, Frederic Moulin, Michelle J Nophsker, Ying-Kai Wang, Mengping Liu, Karen Rigat, Yong Tub, Piyasena Hewawasam, John Kadow, Nicholas A. Meanwell, Mark Cockett, Julie Lemm, Melissa Kramer, Makonen Belema, Min Gao, Nature, 2015, 527, 245-248
• Comparison of Daclatasvir Resistance Barriers on NS5A from Hepatitis C Virus Genotypes 1 to 6: Implications for Cross-Genotype Activity, Chunfu Wang, Lingling Jia, Donald R. O’Boyle II, Jin-Hua Sun, Karen Rigat, Lourdes Valera, Peter Nower, Xin Huang, Bernadette Kienzle, Susan Roberts, Min Gao, Robert A. Fridell, Antimicrobial Agents and Chemotherapy, 2014, 58, 9, 5155-5163
• Hepatitis C Virus NS5A Replication Complex Inhibitors, Part 6: Discovery of a Novel and Highly Potent Biarylimidazole Chemotype with Inhibitory Activity Toward Genotypes 1a and 1b Replicons, Makonen Belema, Van N. Nguyen, Jeffrey L. Romine, Denis R. St. Laurent, Omar D. Lopez, Jason T. Goodrich, Peter T. Nower, Donald R. O’Boyle II, Julie A. Lemm, Robert A. Fridell, Min Gao, Hua Fang, Rudolph G. Krause, Ying-Kai Wang, A. Jayne Oliver, Andrew C. Good, Jay O. Knipe, Nicholas A. Meanwell, Lawrence B. Snyder, Journal of Medicinal Chemistry, 2014, 57, 5, 1995-2012
• Characterizations of HCV NS5A Replication Complex Inhibitors, Donald R. O'Boyle II, Jin-Hua Sun, Peter T. Nower, Julie A. Lemm, Robert A. Fridell, Chunfu Wang, Jeffrey L. Romine, Makonen Belema, Van N. Nguyen, Denis R. St. Laurent, Michael Serrano-Wu, Lawrence B. Snyder, Nicholas A. Meanwell, David R. Langley, Min Gao, Virology, 2013, 444, 1-2, 343-354
• HCV NS5A Replication Complex Inhibitors. Part 5: Discovery of Potent and Pan-genotypic Glycinamide Cap Derivatives, Makonen Belema, Van N. Nguyen, Denis R. St. Laurent, Omar D. Lopez, Yuping Qiu, Andrew C. Good, Peter T. Nower, Lourdes Valera, Donald R. O’Boyle II, Jin-Hua Sun, Mengping Liu, Robert A. Fridell, Julie A. Lemm, Min Gao, Jay O. Knipe, Nicholas A. Meanwell, Lawrence B. Snyder, Bioorganic & Medicinal Chemistry Letters, 2013, 23, 15, 4428-4435
• A 96-well Based Analysis of Replicon Elimination with the HCV NS5A Replication Complex Inhibitor Daclatasvir, Donald R. O’Boyle II, Peter T. Nower, Jin-Hua Sun, Robert Fridell, Chunfu Wang, Lourdes Valera, Min Gao, Journal of Virological Methods, 2013, 193, 1, 68-76
• HCV NS5A Replication Complex Inhibitors. Part 4.1 Optimization for Genotype 1a Replicon Inhibitory Activity, Denis R. St. Laurent, Michael H. Serrano-Wu, Makonen Belema, Min Ding, Hua Fang, Min Gao, Jason T. Goodrich, Rudolph G. Krause, Julie A. Lemm, Mengping Liu, Omar D. Lopez, Van N. Nguyen, Peter T. Nower, Donald R. O’Boyle, Bradley C. Pearce, Jeffrey L. Romine, Lourdes Valera, Jin-Hua Sun, Ying-Kai Wang, Fukang Yang, Xuejie Yang, Nicholas A. Meanwell, Lawrence B. Snyder, Journal of Medicinal Chemistry, 2013, 57, 5, 1976-1994
• HCV NS5A Replication Complex Inhibitors. Part 3: Discovery of Potent Analogs with Distinct Core Topologies, Omar D. Lopez, Van N. Nguyen, Denis R. St. Laurent, Makonen Belema, Michael H. Serrano-Wu, Jason T. Goodrich, Fukang Yang, Yuping Qiu, Amy S. Ripka, Peter T. Nower, Lourdes Valera, Mengping Liu, Donald R. O’Boyle, Jin-Hua Sun, Robert A. Fridell, Julie A. Lemm, Min Gao, Andrew C. Good, Nicholas A. Meanwell, Lawrence B. Snyder, Bioorganic & Medicinal Chemistry Letters, 2013, 23, 3, 779-784
• Persistence of Resistant Variants in HCV Infected Patients Treated with the NS5A Replication Complex Inhibitor Daclatasvir, Chunfu Wang, Jin-Hua Sun, Donald R. O’ Boyle II, Peter Nower, Lourdes Valera, Susan Roberts, Robert A. Fridell, Min Gao, Antimicrobial Agents and Chemotherapy, 2013, 57, 5, 2054-2065
• Investigation of Stilbene Prolinamides, R. St. Laurent, Makonen Belema, Min Gao, Jason Goodrich, Ramesh Kakarla, Jay O. Knipe, Julie A. Lemm, Mengping Liu, Omar D. Lopez, Van N. Nguyen, Peter T. Nower, Donald O’Boyle II, Yuping Qiu, Jeffrey L. Romine, Michael H. Serrano-Wu, Jin-Hua Sun, Lourdes Valera, Fukang Yang, Xuejie Yang, Nicholas A. Meanwell, Lawrence B. Snyder, Bioorganic & Medicinal Chemistry Letters, 2012, 22, 19, 6063-6066
• In Vitro Activity of BMS-790052 on Hepatitis C Virus Genotype 4 NS5A, Chunfu Wang, Haichang Huang, Lourdes Valera, Jin-Hua Sun, Donald O’Boyle II, Peter Nower, Lingling Jia, Dike Qiu, Xin Huang, Aneela Altaf, Min Gao, Robert A. Fridell, Antimicrobial Agents and Chemotherapy, 2012, 56, 3, 1588-1590
• Impact of a Baseline Polymorphism on the Emergence of Resistance to the Hepatitis C Virus Nonstructural Protein 5a Replication Complex Inhibitor, BMS-790052, Jin-Hua Sun, Donald R. O’ Boyle II, Chunfu Wang, Peter Nower, Lourdes Valera, Susan Roberts, Richard E. Nettles, Robert A. Fridell, Min Gao, Hepatology, 2012, 55, 6, 1692-1699
• Hepatitis C Virus RNA Elimination and Development of Resistance in Replicon Cells Treated with BMS-790052, Chunfu Wang, Haichang Huang, Lourdes Valera, Jin-Hua Sun, Donald O’Boyle II, Peter Nower, Lingling Jia, Dike Qiu, Xin Huang, Aneela Altaf, Min Gao, Robert A. Fridell, Antimicrobial Agents and Chemotherapy, 2012, 56, 3, 1350-1358
• The Effects of NS5A Inhibitors on NS5A Phosphorylation, Polyprotein Processing and Localization, Dike Qiu, Julie A. Lemm, Donald R. O’Boyle II, Jin-Hua Sun, Peter T. Nower, Van Nguyen, Lawrence G. Hamann, Lawrence B. Snyder, Daniel H. Deon, Edward Ruediger, Nicholas A. Meanwell, Makonen Belema, Min Gao, Robert A. Fridell, Journal of General Virology, 2011, 92, 11, 2502-2511
• Genotypic and Phenotypic Analysis of Variants Resistant to Hepatitis C Virus Nonstructural Protein 5A Replication Complex Inhibitor BMS-790052 in Humans: In Vitro and In Vivo Correlations, Robert A. Fridell, Chunfu Wang, Jin-Hua Sun, Donald R. O'Boyle II, Peter Nower, Lourdes Valera, Dike Qiu, Susan Roberts, Xin Huang, Bernadette Kienzle, Marc Bifano, Richard E. Nettles, Min Gao, Hepatology, 2011, 54, 6, 1924-1935
• Discovery of Potent Hepatitis C Virus NS5A Inhibitors with Dimeric Structures, Julie A. Lemm, John E. Leet, Donald R. O’Boyle II, Jeffrey L. Romine, Xiaohua Stella Huang, Daniel R. Schroeder, Jeffrey Alberts, Joseph L. Cantone, Jin-Hua Sun, Peter T. Nower, Scott W. Martin, Michael H. Serrano-Wu, Nicholas A. Meanwell, Lawrence B. Snyder, Min Gao, Antimicrobial Agents and Chemotherapy, 2011, 55, 8, 3795-3802
• Inhibitors of HCV NS5A: From Iminothiazolidinones to Symmetrical Stilbenes, Jeffrey L. Romine, Denis R. St. Laurent, John E. Leet, Scott W. Martin, Michael H. Serrano-Wu, Fukang Yang, Min Gao, Donald R. O'Boyle II, Julie A. Lemm, Jin-Hua Sun, Peter T. Nower, Xiaohua Huang, Milind S. Deshpande, Nicholas A. Meanwell, Lawrence B. Snyder, ACS Medicinal Chemistry Letters, 2011, 2, 3, 224-229
• Identification of Hepatitis C Virus NS5A Inhibitors, Julie A. Lemm, Donald O'Boyle II, Mengping Liu, Peter T. Nower, Richard Colonno, Milind S. Deshpande, Lawrence B. Snyder, Scott W. Martin, Denis R. St. Laurent, Michael H. Serrano-Wu, Jeffrey L. Romine, Nicholas A. Meanwell, Min Gao, Journal of Virology, 2010, 84, 1, 482-491
• Development of a Cell-Based High-Throughput Specificity Screen Using a Hepatitis C Virus-Bovine Viral Diarrhea Virus Dual Replicon Assay, Donald R. O’Boyle II, Peter T. Nower, Julie A. Lemm, Lourdes Valera, Jin-Hua Sun, Karen Rigat, Richard Colonno, Min Gao, Antimicrobial Agents and Chemotherapy, 2005, 49, 4, 1346-1353
• Reaction of HIV-1 NC P7 Zinc Fingers with Electrophilic Reagents, E. Chertova, B. P. Kane, L. V. Cohen, D. G. Johnson, R. C. Sowder II, P. Nower, J. R. Casas-Finet, L. O. Arthur, L. E. Henderson, Techniques in Protein Chemistry, 1997, 231-244
• 2',3'-Cyclopropanated Nucleoside Dimers, Constantin Yannopoulos, Wen-Qiang Zhou, Peter Nower, Didier Peoc'h, Yogesh Sanghvi, George Just, Synlett, 1997, 1997, 4, 378-380
• Phorbal Esters Inhibit Insulin-Induced Receptor Down-Regulation in Cultured Human Lymphocytes: Association with Diminished Insulin Receptor Autophosphorylation, K. Torossian, P. Nower, T. Schwartz, I. G. Fantus, The Biochemical Journal, 1993

• 96-, 384-, and 1536-well cell-based assay development and validation for HTS (HiBiT, Luciferase reporter, ion channel, receptor binding, HTRF, BRET, FRET, Absorbance and Cytotox)
• Lab automation: Perkin Elmer Envision, Thermofisher Multi Drop Combi, Integra Viaflow liquid handler, Vi-Cell Blu cell counter, Leica DM IL LED Fluor Inverted Fluorescence Tissue Culture Microscope, Zebra ZD620 label printer, ViewLux, Hamamatsu FDSS7000EX, Barracuda with Automated Patch Clamp System, fully automated workstations, Echo, CyBio and Tempest liquid handlers and electronic data analysis (Genedata, Scilligence, ACAS, Toolset, Curvemaster, PRISM and Spotfire)
• Molecular biology techniques: RT-PCR, PCR (primer construction, cDNA and DNA cloning), qPCR, plasmid preps, site directed mutagenesis, DNA Sequencing, RNA & DNA isolation, electroporation and chemical based transient transfections
• Protein expression, purification, ELISA, SDS-PAGE, Western and dot blotting, Streptavidin and FLAG tag affinity chromatography, immunoprecipitation and in vitro translation
• Generation, characterization and maintenance of cell lines (SW1573, MiaPaCa-2, AsPC-1, A549-Dual adherent epithelials, HEK293, CHO, HEP G2, HUH-7, THP-1)

• Arvinas, Research Scientist, 07/15/19, 04/30/25, Cell based HiBiT assay development and optimization, Screening / Characterization of program compounds in either 1) multiple cell types simultaneously or 2) biochemical assays while ensuring strong robust assay performance., Reviewed data for completeness and accuracy., Mammalian cell culture, SDS-PAGE/Western blotting, Maintenance (banking & retrieving) of 12,000 + vial cell repository, Preparation of compound plates, Weekly analysis of proliferation and degradation PAN KRAS program, Reported weekly proliferation and degradation results within 24 window of assay completion, Presented monthly PAN KRAS program status compound performance report to the PAN KRAS biology group., Integration of multiple analysis programs to analyze compound over the years (KNIME, Scilligence, Genedata)., Maintained KRAS chemical matter received from EVOTEC, Maintained a compliant Electronic Notebook (ELN), Met weekly with supervisor, Maintained a tidy and productive lab environment, Good Lab citizen, 2021 Arvinas Impact award, 2022 CEO Excellence award, 2024 CEO Excellence award, 2025 CEO Excellence award
• Bristol-Myers Squibb Pharmaceutical Research Institute, Research Scientist II - Lead Discovery and Optimization, 10/96, 07/19, Assay development and validation for high-throughput screening, Fields of Study: Immuno-oncology (EP2/EP4, TLR3 and RIG-I), Cardiovascular (AT1R), Ion channels, GPCR, Perform weekly lead profiling and monthly safety panel ion-channel assays (assay development/troubleshooting) to characterize small molecule inhibitors
• Bristol-Myers Squibb Pharmaceutical Research Institute, Research Scientist II - Department of Virology, 10/96, 12/15, Developed and validated anti-viral assays, executed assays for screening purposes, and performed mechanism of action studies., Fields of Study: HCV, HBV, BVDV, HIV., Demonstrated that active NS5a inhibitors bind selectively and non-covalently to NS5a protein using biotin-tagged derivative of Daklinza, Developed cell-based assays to define the selectivity of small molecule inhibitors, Mammalian cell culture and aseptic technique experience, Transient expression of recombinant proteins, SDS-PAGE/Western blotting, Protein quantification
• NCI, Frederick Cancer Research and Development Center, Research Associate - AIDS Vaccine Program (AVP)/HIV Nucleocapsid Drug Screen Section, 1995, 1996, Developed, performed and optimized novel fluorometric assays focused on discovering new chemotypes that could inactivate nucleocapsid protein (p7)., Executed rates of reaction and mechanism of action studies.

• Ice hockey
• Golf
• Pickleball

• 2002 BMS Triumph LDOC Award: “Development of a ell-based, proprietary replicon system for measuring the activity of inhibitors against Hepatitis C virus and for identifying two novel classes
• 2021 Arvinas Impact award
• 2022 CEO Excellence award
• 2024 CEO Excellence award
• 2025 CEO Excellence award